2015
DOI: 10.1038/hr.2015.129
|View full text |Cite
|
Sign up to set email alerts
|

Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism

Abstract: Background: The mineralocorticoid receptor (MR) is expressed in the kidneys and in adipose tissue, and

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

1
31
2
2

Year Published

2017
2017
2023
2023

Publication Types

Select...
6
3
1

Relationship

0
10

Authors

Journals

citations
Cited by 62 publications
(36 citation statements)
references
References 36 publications
1
31
2
2
Order By: Relevance
“…Multiple administrations of eplerenone also resulted in dose‐dependent elevations in serum aldosterone in patients with mild‐to‐moderate hypertension . Both eplerenone (25–100 mg daily) and spironolactone (12.5–100 mg daily) for 12 months significantly increased PRA and PAC in patients with primary aldosteronism . Multiple administrations of esaxerenone for 10 days increased PRA, ARC and PAC in a time‐ and dose‐dependent manner in healthy male subjects (Figure A–C).…”
Section: Discussionmentioning
confidence: 89%
“…Multiple administrations of eplerenone also resulted in dose‐dependent elevations in serum aldosterone in patients with mild‐to‐moderate hypertension . Both eplerenone (25–100 mg daily) and spironolactone (12.5–100 mg daily) for 12 months significantly increased PRA and PAC in patients with primary aldosteronism . Multiple administrations of esaxerenone for 10 days increased PRA, ARC and PAC in a time‐ and dose‐dependent manner in healthy male subjects (Figure A–C).…”
Section: Discussionmentioning
confidence: 89%
“…Further grounds for a cause and effect dependence between hyperaldosteronism and metabolic syndrome is sustained analyzing the phenotype of a new transgenic mice model bearing a selective overexpression of MRs in adipocytes, which is characterized by insulin resistance and increased visceral fat mass, body weight and plasma triglycerides levels (51). "Karashima et al analyzed adult patients with hyperaldosteronism but without abdominal obesity (52). The authors found that the effects of eplerenone on different variables-including body mass index and visceral adipose tissue-were reduced, as measured by computed tomography and fat scan, although the BMI of the participants was rather normal and suggested no redistribution of fat (52).…”
Section: Discussionmentioning
confidence: 99%
“…Spironolactone further induced hepatocyte expression of lipogenic enzymes, supporting a more direct role of androgen receptors within hepatocytes on lipid metabolism (39). Likewise, short course spironolactone trials in humans have shown decreased visceral adiposity (40) and serum free fatty acids (41). Taken together, these data suggest that anti-androgen therapy may help to improve metabolic co-morbidities, and their role in NAFLD development and progression in women may warrant exploration.…”
Section: Discussionmentioning
confidence: 99%